J17

J17 is a synthetic curcumin derivative developed by the Salk Institute for Biological Studies as a neuroprotective agent. It was designed as part of a series of hybrid compounds (including the more advanced candidate J147) that combine the structural features of curcumin and cyclohexyl-bis-phenol A to enhance bioavailability and potency. J17 exhibits neurotrophic and neuroprotective activities in cell culture models of age-associated neurodegeneration. Its mechanism of action involves the protection of mitochondrial function and the reduction of oxidative stress, which are critical pathways in the pathogenesis of Alzheimer's disease and other neurodegenerative disorders. While J17 showed promising results in preclinical studies, including the ability to improve memory in rodent models, it has primarily served as a lead compound for the development of more potent analogs like J147.

Other names

curcumin derivative J17